HPV相关口咽癌治疗后的监测性PET/CT
该回顾性病历回顾纳入233例HPV相关口咽鳞状细胞癌患者,评估监测性PET/CT的诊断准确性、下游临床影响和生存。监测性PET/CT阴性预测值和灵敏度均为100%,特异度59.9%,阳性预测值13.4%;仅1.6%的病例因此获得有意义的挽救治疗,且PET/CT发现的复发与临床发现的复发相比生存无改善。
要点
- 监测性PET/CT阴性预测值和灵敏度均为100%,特异度59.9%,阳性预测值13.4%。
- 监测性PET/CT导致90次影像检查和31次活检,分别有91.1%和77.4%为复发阴性。
- 仅1.6%的病例因监测性PET/CT获得有意义的挽救治疗,且未显示生存获益。
核心结论
- 对于HPV相关口咽鳞状细胞癌患者,监测性PET/CT常导致不必要的检查,很少带来有意义的疾病挽救,未显示生存获益,应谨慎解读以避免患者伤害。
研究设计与样本
- 回顾性病历回顾,纳入233例HPV相关口咽鳞状细胞癌患者,评估监测性PET/CT的诊断准确性、下游临床影响和生存。
主要发现
- 监测性PET/CT的阴性预测值和灵敏度均为100%,特异度为59.9%,阳性预测值为13.4%。
- 监测性PET/CT导致90次影像检查和31次活检,其中91.1%的影像检查和77.4%的活检为复发阴性。
- 监测性PET/CT使1.6%的病例获得有意义的挽救治疗。
- PET/CT检测到的复发与临床检测到的复发相比,生存无改善。
临床怎么用
- 作者认为,对于HPV相关口咽鳞状细胞癌患者,监测性PET/CT应谨慎解读以避免患者伤害。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surveillance positron emission tomography-computed tomography (PET/CT) is commonly used for treatment assessment of radiation therapy in head and neck cancer. However, human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC) patients represent a unique subpopulation, for which the utility of surveillance PET/CT has not been well studied. METHODS: In this retrospective chart review comprising 233 HPV+OPSCC patients, we evaluated surveillance PET/CT for diagnostic accuracy, downstream clinical impact, and survival. RESULTS: Surveillance PET/CT demonstrated 100% negative predictive value and sensitivity, 59.9% specificity, and 13.4% positive predictive value. Surveillance PET/CT led to 90 imaging studies and 31 biopsies; 91.1% and 77.4% were negative for recurrence, respectively. Surveillance PET/CT led to meaningful salvage therapy in 1.6% of cases. PET/CT-detected recurrences did not have improved survival compared to clinically detected recurrences. CONCLUSION: For HPV+OPSCC patients, surveillance PET/CTs frequently lead to unnecessary testing and rarely to meaningful disease salvage. They have no demonstrated survival benefit and should be interpreted cautiously to prevent patient harm.
引用
- Corpman DW, Masroor F, Carpenter DM, et al. Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer. Head Neck. 2018. PMID: 30549345. doi:10.1002/hed.25425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。